Research output per year
Research output per year
Search results
-
2024
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
Fehniger, T. A., Watkins, M. P., Ezenwajiaku, N., Wan, F., Hurd, D. D., Cashen, A. F., Blum, K. A., Goy, A., Fenske, T. S., Wagner-Johnston, N. D., Carson, K., Siegel, M. J., Russler-Germain, D., Schneider, S. E., Mehta-Shah, N., Kahl, B. & Bartlett, N. L., Mar 2024, In: Haematologica. 109, 3, p. 953-957 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations -
2023
FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma
Russler-Germain, D. A., Calhoun, B. R., Wu, N., Watkins, M. P., Siegel, B. A., Bartlett, N. L. & Mhlanga, J. C., 2023, In: Leukemia and Lymphoma. 64, 11, p. 1870-1874 5 p.Research output: Contribution to journal › Letter › peer-review
1 Scopus citations -
2022
Idecabtagene vicleucel: questions regarding the appropriate role and cost
Powell, K., Russler-Germain, D. & Prasad, V., Jan 2022, In: British Journal of Haematology. 196, 2, p. e15-e16Research output: Contribution to journal › Letter › peer-review
Open Access4 Scopus citations -
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
Eastburg, L., Russler-Germain, D. A., DiPersio, J. F., Fountaine, T., Andolina, J. R., Abboud, R. & Huselton, E., 2022, In: Leukemia and Lymphoma. 63, 1, p. 222-226 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations -
2021
A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma
Russler-Germain, D. A., Watkins, M. P. & Bartlett, N. L., 2021, In: Leukemia and Lymphoma. 62, 2, p. 486-488 3 p.Research output: Contribution to journal › Letter › peer-review